MILESTONE SCIENTIFIC INC.MLSSEarnings & Financial Report
Boston Scientific Corporation (BSC) is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
MLSS Q4 FY2025 Key Financial Metrics
Revenue
$2.1M
Gross Profit
$1.5M
Operating Profit
$-1.1M
Net Profit
$-1.1M
Gross Margin
73.0%
Operating Margin
-52.5%
Net Margin
-53.0%
YoY Growth
2.2%
EPS
$-0.02
MILESTONE SCIENTIFIC INC. Q4 FY2025 Financial Summary
MILESTONE SCIENTIFIC INC. reported revenue of $2.1M (up 2.2% YoY) for Q4 FY2025, with a net profit of $-1.1M (up 46.4% YoY) (-53.0% margin). Cost of goods sold was $556.3K, operating expenses totaled $2.6M.
Key Financial Metrics
| Total Revenue | $2.1M |
|---|---|
| Net Profit | $-1.1M |
| Gross Margin | 73.0% |
| Operating Margin | -52.5% |
| Report Period | Q4 FY2025 |
MILESTONE SCIENTIFIC INC. Annual Revenue by Year
MILESTONE SCIENTIFIC INC. annual revenue history includes year-by-year totals (for example, 2025 revenue was $9.0M).
MILESTONE SCIENTIFIC INC. Quarterly Revenue & Net Profit History
MILESTONE SCIENTIFIC INC. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $2.1M | +2.2% | $-1.1M | -53.0% |
| Q3 FY2025 | $2.4M | -6.1% | $-1.2M | -48.9% |
| Q2 FY2025 | $2.3M | +25.3% | $-1.5M | -63.8% |
| Q1 FY2025 | $2.2M | -0.7% | $-2.0M | -89.3% |
| Q4 FY2024 | $2.0M | -10.9% | $-2.0M | -101.1% |
| Q3 FY2024 | $2.5M | +22.1% | $-1.5M | -58.1% |
| Q2 FY2024 | $1.9M | -36.3% | $223.6K | 12.1% |
| Q1 FY2024 | $2.2M | -13.4% | $-1.4M | -64.1% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $1.9M | $2.5M | $2.0M | $2.2M | $2.3M | $2.4M | $2.1M |
| YoY Growth | -13.4% | -36.3% | 22.1% | -10.9% | -0.7% | 25.3% | -6.1% | 2.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $11.4M | $12.0M | $11.2M | $9.8M | $9.1M | $8.1M | $8.5M | $7.8M |
| Liabilities | $3.9M | $4.1M | $4.0M | $4.0M | $4.6M | $4.7M | $5.9M | $5.0M |
| Equity | $7.5M | $8.0M | $7.2M | $5.8M | $4.5M | $3.3M | $2.5M | $2.8M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.2M | $783655 | $-973914 | $-1.5M | $-1.0M | $-1.8M | $81775 | $-226129 |